Tscan Therapeutics Inc (TCRX) Stock Price, Quote & News

Company Profile

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 399 9500

Website: www.tscan.com

Address:

830 Winter Street, Waltham, United States

JSP_Dilution_Player Jan. 28 at 4:31 PM

$TCRX wakeup management. IND was supposed to be in 2nd half of 2025. Now we are in end of Jan. I am expecting IND news by mid Feb if already submitted in 1st week of Jan. Trading way below cash and funds into 2nd half of 2027.

0 · Reply

JSP_Dilution_Player Jan. 27 at 4:40 PM

$TCRX looking better today. let's see if this get over 1.2 this week.

0 · Reply

JSP_Dilution_Player Jan. 25 at 11:26 PM

$FATE $TCRX one of these should pop to 1.5. Both are trading way under cash. TCRX has IND News pending.

0 · Reply

RMND Jan. 20 at 3:11 PM

$TCRX

0 · Reply

OfficialStocktwitsUser Jan. 19 at 8:42 PM

$TCRX RSI: 58.54, MACD: 0.0222 Vol: 0.11, MA20: 1.07, MA50: 1.06 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply